COMPOSITIONS,USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES

The invention relates to a fusion of fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21) and its use in the treatment of hyperglycemic condition, insulin resistance, hyperinsulinemia, glucose intolerance, metabolic syndrome, obesity, undesirable body mass, nonalcoholic fatty...

Full description

Saved in:
Bibliographic Details
Main Authors LINDHOUT,DARRIN A, LING,LEI
Format Patent
LanguageEnglish
Published 30.08.2017
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a fusion of fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21) and its use in the treatment of hyperglycemic condition, insulin resistance, hyperinsulinemia, glucose intolerance, metabolic syndrome, obesity, undesirable body mass, nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH), atherosclerosis and related disorders.
Bibliography:Application Number: ZA20150008231